临床试验/CTIS2023-506402-39-00

CTIS2023-506402-39-00进行中（未招募）1 期

HFB-301001-01

Hifibio Inc.0 个研究点目标入组 170 人开始时间: 2023年8月25日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Hifibio Inc.
入组人数: 170

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

未提供

排除标准

未提供

研究者

发起方

相似试验

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104

CTIS2024-511286-11-00Hifibio Inc.376

A Study of NB003 in Patients With Advanced Malignancies

CTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid TumorsPatients with Advanced Solid Tumors

CTIS2023-506390-35-00Tesaro Inc.840

Safety and Tolerability of AC01 in patients with heart failureMedDRA version: 20.0Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541Heart Failure

CTIS2022-500347-20-00Anacardio AB116

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung CancerOncologyMedDRA version: 21.1Level: PTClassification code: 10029517Term: Non-small cell lung cancer stage I Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029516Term: Non-small cell lung cancer stage 0 Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029518Term: Non-small cell lung cancer stage II Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029519Term: Non-small cell lung cancer stage III Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029515Term: Non-small cell lung cancer recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029520Term: Non-small cell lung cancer stage IIIA Class: 100000004864

CTIS2023-506539-14-00Systimmune Inc.144